OR WAIT null SECS
February 27, 2024
CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.
February 20, 2024
FDA has approved Iovance Biotherapeutics’ Amtagvi (lifileucel) for treating patients with unresectable or metastatic melanoma.
February 01, 2024
The final guidance provides specific recommendations for CMC, pharmacology, toxicology, and clinical study design for CAR-T cell products.
January 11, 2024
Pluri has launched PluriCDMO, a new contract development and manufacturing organization business that will offer cell therapy manufacturing services.
January 04, 2024
AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.
January 03, 2024
Revolutionary therapies restructure pharmaceutical manufacturing.
There are positive indications for future growth.
Buffers, stabilizers, and cryoprotectants play major roles in cell therapy formulations.
December 29, 2023
Through Syena, its oncology-focused product company, Replay will develop and manufacture T-cell receptor and natural killer cell therapies with the NIH and Miltenyi Biotec.
December 28, 2023
Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.